Marco Testa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marco Testa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Massimo Volpe
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
2 shared publications - Erica Gabriele
Sapienza University of Rome
1 shared publication - Matteo Casenghi
Department of Cardiology Sant'Andrea Hospital Rome Italy
1 shared publication - Roberta Coluccia
Sapienza University of Rome
1 shared publication - Speranza Rubattu
IRCCS Neuromed, 86077 Pozzilli, Italy
1 shared publication - Vittoria Mastromarino
Department of Clinical and Molecular Medicine, Sapienza University, 00100 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 6 March 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (10) , 800-802
Tales in Cardiology
I see no reason or need for my doctor to love me—nor would I expect him to suffer with me. I wouldn’t demand a lot of my doctor’s time: I just wish he would bro
- 6 March 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (10) , 800-802
Open AccessTales in Cardiology
I see no reason or need for my doctor to love me—nor would I expect him to suffer with me. I wouldn’t demand a lot of my doctor’s time: I just wish he would bro
- 4 February 2014
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 11 (2) , 212-219
Polypharmacy in Heart Failure Patients
In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines. With HF being a common disease in the elderly, patients often have numerous comorbidities that require additional specific treatment, thus producing a heavy pill burden. Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients. However, polypharmacy has an important impact on HF treatment, as it often leads to inappropriate drug prescription, poor adherence to pharmacological therapies, drug-drug interactions, and adverse effects. The growing complexity of HF patients, whose mean age increases progressively and who present multiple comorbidities, suggests the need for newer models of primary care to improve the management of HF patients. Self-care, telemonitoring, and natriuretic peptide-guided therapy represent promising new HF care models to face the complexity of the disease and its therapeutic regimen.
- 4 February 2014
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 11 (2) , 212-219
Polypharmacy in Heart Failure Patients
In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines. With HF being a common disease in the elderly, patients often have numerous comorbidities that require additional specific treatment, thus producing a heavy pill burden. Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients. However, polypharmacy has an important impact on HF treatment, as it often leads to inappropriate drug prescription, poor adherence to pharmacological therapies, drug-drug interactions, and adverse effects. The growing complexity of HF patients, whose mean age increases progressively and who present multiple comorbidities, suggests the need for newer models of primary care to improve the management of HF patients. Self-care, telemonitoring, and natriuretic peptide-guided therapy represent promising new HF care models to face the complexity of the disease and its therapeutic regimen.